DCF — HONORHEALTH SCOTTSDALE OSBORN MED CT
Enterprise Value: $-53.7M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-53.7M
Enterprise Value
$-28.3M
PV of Cash Flows
$-25.4M
PV of Terminal Value
$-40.8M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $453.2M | $5.8M | 1.0% | $-13.4M | $-12.2M |
| Year 2 | $466.8M | $10.6M | 2.0% | $-9.1M | $-7.5M |
| Year 3 | $480.8M | $15.8M | 3.0% | $-5.5M | $-4.1M |
| Year 4 | $495.2M | $18.7M | 4.0% | $-3.8M | $-2.6M |
| Year 5 | $510.1M | $20.6M | 4.0% | $-3.0M | $-1.9M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-53.7M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$440.0M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.00779712200593256
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5